Role of STAT3 Dependent SOX2 and CD24 Expression in Melanoma Cell Adaptive Resistance Towards Targeted Therapies

Oncotarget - United States
doi 10.18632/oncotarget.26718
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Impact Journals, LLC

Related search

SOX2-mediated Upregulation of CD24 Promotes Adaptive Resistance Towards Targeted Therapy in Melanoma

International Journal of Cancer
Cancer ResearchOncology
2018English

New Role of ID3 in Melanoma Adaptive Drug-Resistance

Oncotarget
Oncology
2017English

Targeted Therapies in Cancer and Mechanisms of Resistance

Journal of Molecular Medicine
Molecular MedicineDrug DiscoveryGenetics
2014English

Rationale for Targeted Therapies and Potential Role of Pazopanib in Advanced Renal Cell Carcinoma

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2010English

Current Perspectives in Metastatic Renal Cell Carcinoma Treatment: The Role of Targeted Therapies

2013English

Paradox of B Cell–targeted Therapies

Journal of Clinical Investigation
Medicine
2008English

Resistance to Proteasome Inhibitors and Other Targeted Therapies in Myeloma

British Journal of Haematology
Hematology
2018English

Metastasis Targeted Therapies in Renal Cell Cancer

Üroonkoloji Bülteni
2018English

Dermatomyositis: A Slow Path Towards Targeted Therapies or Will Conventional Therapies Prevail?

British Journal of Dermatology
DermatologyMedicine
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy